Skip to main content

Table 4 Combination therapy with targets in downstream signaling pathways

From: Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Target Representative compound* Structure Reference
MEK Trametinib [155, 156]
MEK Selumetinib [155,156,157]
MEK PD0325901 [155]
AKT Uprosertib (GSK2141795) [158]
AKT Capivasertib (AZD5363) [158]
AXL Cabozantinib [159]
AXL DS-1205b [160]
AXL Yuanhuadine (YD) [161]
AXL Bemcentinib (R428) [162]
ACK1 (R)-9b [163, 164]
  1. *Osimertinib is a representative third-generation EGFR-TKI